00:03 , Dec 16, 2017 |  BC Extra  |  Company News

Management tracks: Chugai, bioMérieux

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said President and COO Tatsuro Kosaka will become president and CEO. He succeeds CEO Osamu Nagayama, who will remain chairman. Diagnostics company bioMérieux S.A. (Euronext:BIM) said Deputy CEO Alexandre Mérieux...
19:10 , Jul 14, 2017 |  BC Week In Review  |  Company News

Konica Minolta to acquire Ambry Genetics for up to $1B in shift to precision medicine

Konica Minolta Inc. (Tokyo:4902) will acquire genetic testing company Ambry Genetics Corp. (Aliso Viejo, Calif.) for up to $1 billion. Ambry shareholders will receive $800 million in cash up front and up to $200 million...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Ambry Genetics, Myriad Genetics diagnostic news

The U.S. Court of Appeals for the Federal Circuit (CAFC) ruled that a district court correctly denied Myriad’s motion for preliminary injunction against Ambry for Ambry’s standalone breast cancer 1 early onset (BRCA1) and BRCA2...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Ambry Genetics, Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering, University of Pennsylvania cancer news

Ambry and researchers from Dana-Farber, Mayo Clinic, Memorial Sloan Kettering and the university's Abramson cancer center partnered in the Prospective Registry of MultiPlex Testing (PROMPT) to create an online registry for patients that have undergone...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Myriad Genetics Inc, Pathway Genomics diagnostic news

Myriad filed suit against Pathway in the U.S. District Court for the District of Utah, Central division alleging that Pathway’s BRCATrue gene test infringes 13 Myriad patents related to the breast cancer 1 early onset...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Ambry Genetics sales and marketing update

Ambry launched the ExomeNext and ExomeNext-Rapid assays for exome sequencing in a clinical setting. ExomeNext has a list price of $5,800 and provides results in eight to 12 weeks. ExomeNext-Rapid has a list price of...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Ambry Genetics, Myriad Genetics diagnostic news

The U.S. District Court for the District of Utah denied Myriad's motion for preliminary injunction against Ambry for Ambry's standalone breast cancer 1 early onset (BRCA1) and BRCA2 tests. In University of Utah Research Foundation...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Gene by Gene, Myriad Genetics diagnostic news

Gene by Gene and Myriad settled a July suit under which Myriad was alleging Gene by Gene infringed nine patents held or licensed by Myriad covering synthetic DNA and methods of use related to the...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Pathway Genomics management update

Pathway Genomics Corp. , San Diego, Calif.   Business: Diagnostic   Hired: Ardy Arianpour as chief strategy officer, formerly SVP of business development at Ambry Genetics Crop.  ...